Radiotherapy plays a pivotal role in the management of non-small-cell lung cancer (NSCLC). However, clinicians often struggle to predict how tumors will respond during the course of treatment. Recent research into CBCT radiomics lung cancer applications suggests a breakthrough in monitoring these patients. By analyzing imaging data from daily cone-beam computed tomography (CBCT), doctors can now assess tumor regression volume more accurately. This approach allows for timely adjustments to treatment plans. Consequently, it improves the precision of radiation delivery to the affected area.

The study utilized two distinct patient datasets to validate the reliability of radiomics features. Initially, researchers extracted 34 robust features from planning CT and early CBCT scans. They specifically looked for reproducible "delta radiomics" features. These features represent the quantitative changes in the tumor’s appearance over time. Furthermore, the analysis identified sixteen delta features that remained consistent across different imaging modalities. Nine of these showed significant differences during the early phase of radiotherapy.

Improving Treatment Precision with CBCT Radiomics Lung Cancer

Ultimately, the researchers identified four specific delta radiomics features that predict tumor regression volume. They used a 30% threshold to classify these responses effectively. This finding is significant because it proves the feasibility of using existing CBCT data for advanced analysis. Moreover, these features help clinicians identify which patients might require adaptive treatment planning. Therefore, this novel strategy offers a reliable way to optimize outcomes. It ensures that therapy remains effective even as the tumor changes shape and size.

In conclusion, the study demonstrates that CBCT-based delta radiomics is a feasible tool for clinical use. Identifying reliable features helps build stronger predictive models. This technology marks a step forward in personalized oncology for lung cancer patients.

Frequently Asked Questions

What is the benefit of using CBCT for radiomics?

CBCT is routinely performed during radiotherapy for patient positioning. Using this existing data for radiomics provides a non-invasive way to monitor tumor volume without requiring additional diagnostic scans.

How does delta radiomics differ from traditional imaging?

Traditional imaging often focuses on a single point in time. In contrast, delta radiomics tracks quantitative changes in image features over the course of treatment, offering a dynamic view of how the tumor responds.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.

References

1. Zhang F et al. Cone-beam computed tomography-based radiomics for tumour regression assessment during radiotherapy of non-small-cell lung cancer. Cancer Radiother. 2026 Jun 04. doi: undefined. PMID: 42241770.


2. van Timmeren JE et al. Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: evaluation of the added prognostic value for overall survival and locoregional recurrence. Radiother Oncol. 2019;136:78-85.


3. Han X et al. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Eur Radiol. 2024;34(4):2716-2726.